Lundbeck's hopes have high costs: "You won't see us reaching that level in the future"

Pharmaceutical company Lundbeck has upgraded its R&D expenses due to high stakes on migraine drug Vyepti. The level is unnaturally high but will fluctuate in the future, says head of R&D.
Photo: Jens Dresling
Photo: Jens Dresling
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

In the last year, Denmark's second-largest pharmaceutical company, Lundbeck, has upgraded its expenses for research and development, not least due to its major stakes on turning migraine drug Vyepti into a blockbuster.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading